AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 3422243 — intervention group
Group type: COMPARATOR
Intervention: Distilled water
Number of subjects: 24
Study 31068396 — intervention group
Group type: EXPERIMENTAL
Intervention: Live condition (up to 3 live call reminders)
Number of subjects: 1767
Study 31068396 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined automated plus live condition (text message prompt, 2 automated call reminders, and up to 3 live reminders)
Number of subjects: 1767
Study 31068396 — intervention group
Group type: COMPARATOR
Intervention: Automated condition (text message prompt and 2 automated phone call reminders)
Number of subjects: 1767
Study 28277487 — intervention group
Group type: EXPERIMENTAL
Intervention: imPACT
Number of subjects: 405
Study 28277487 — intervention group
Group type: COMPARATOR
Intervention: Standard Care
Number of subjects: 405
Study 25682232 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiotropium 5 μg
Number of subjects: 2103
Study 25682232 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiotropium 2.5 μg
Number of subjects: 2103
Study 25682232 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmeterol 50 μg
Number of subjects: 2103
Study 25682232 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2103
Study 23295684 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D ultrasonography (3DUS) using spatiotemporal image correlation (STIC) method
Number of subjects: 328
Study 21471304 — intervention group
Group type: EXPERIMENTAL
Intervention: Information about harms of waterpipe smoking
Number of subjects: 203
Study 21471304 — intervention group
Group type: COMPARATOR
Intervention: No information (control group)
Number of subjects: 203
Study 19058914 — intervention group
Group type: EXPERIMENTAL
Intervention: Pricking pain (60ms pulse duration)
Number of subjects: 0
Study 19058914 — intervention group
Group type: EXPERIMENTAL
Intervention: Burning pain (2.0s pulse duration)
Number of subjects: 0
Study 19058914 — intervention group
Group type: COMPARATOR
Intervention: Pricking and burning pain (both conditions)
Number of subjects: 0
Study 16525097 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin (500 mg twice a day for 3 days) + Quinine (30 mg/kg/day divided every 8 hours for 3 days)
Number of subjects: 61
Study 16525097 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin (500 mg twice a day for 5 days) + Quinine (30 mg/kg/day divided every 8 hours for 3 days)
Number of subjects: 61
Study 16525097 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin (500 mg three times a day for 3 days) + Quinine (30 mg/kg/day divided every 8 hours for 3 days)
Number of subjects: 61
Study 16525097 — intervention group
Group type: COMPARATOR
Intervention: Quinine (30 mg/kg/day divided every 8 hours for 3 days) + Doxycycline (100 mg twice a day for 7 days)
Number of subjects: 61
Study 14571236 — intervention group
Group type: EXPERIMENTAL
Intervention: Palivizumab (15 mg/kg, intramuscularly, 5 monthly injections)
Number of subjects: 1287
Study 14571236 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1287
Study 11314410 — intervention group
Group type: EXPERIMENTAL
Intervention: Ferric sulfate 15.5% solution (applied for 15 seconds)
Number of subjects: 70
Study 11314410 — intervention group
Group type: COMPARATOR
Intervention: Formocresol solution (five minute procedure of Buckley's formula)
Number of subjects: 70
Study 8994331 — intervention group
Group type: EXPERIMENTAL
Intervention: Parkryl (Mei-Shih), 10 mg per day as an adjunct to Madopar
Number of subjects: 20
Study 8994331 — intervention group
Group type: EXPERIMENTAL
Intervention: Jumexal (Labatec), 10 mg per day as an adjunct to Madopar
Number of subjects: 20
Study 1637548 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5-microns H2SO4 aerosol at approximately 100 micrograms/m3
Number of subjects: 30
Study 1637548 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5-microns carbon aerosol at approximately 250 micrograms/m3
Number of subjects: 30
Study 1637548 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbon aerosol plus approximately 100 micrograms/m3 of ultrafine H2SO4 aerosol
Number of subjects: 30
Study 1637548 — intervention group
Group type: COMPARATOR
Intervention: Clean air
Number of subjects: 30
Study 6546806 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 6546806 — intervention group
Group type: EXPERIMENTAL
Intervention: Pirenzepine, 50 mg twice daily
Number of subjects: 11
Study 6546806 — intervention group
Group type: EXPERIMENTAL
Intervention: Benzilonium bromide, 17.5 mg twice daily
Number of subjects: 11
Study 6546806 — intervention group
Group type: EXPERIMENTAL
Intervention: Benzilonium bromide, 35 mg twice daily
Number of subjects: 11
Study 6546806 — intervention group
Group type: EXPERIMENTAL
Intervention: Benzilonium bromide, 70 mg twice daily
Number of subjects: 11
Study 31026738 — intervention group
Group type: EXPERIMENTAL
Intervention: Brazil nut group (BN), consumed 1 unit/d of Brazil nuts (∼ 1261 μg/Se) for 2 months.
Number of subjects: 55
Study 31026738 — intervention group
Group type: COMPARATOR
Intervention: Control group (CO), did not receive any intervention for 2 months.
Number of subjects: 55
Study 29136476 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy Habits Program (HHP)
Number of subjects: 158
Study 27620390 — intervention group
Group type: EXPERIMENTAL
Intervention: Achieved SBP of 130 to 140 mm Hg in patients aged 50 to <60 years
Number of subjects: 0
Study 27620390 — intervention group
Group type: EXPERIMENTAL
Intervention: Achieved SBP of ≥140 mm Hg in patients aged 50 to <60 years
Number of subjects: 0
Study 27620390 — intervention group
Group type: EXPERIMENTAL
Intervention: Achieved SBP of 130 to 140 mm Hg in patients aged ≥60 years
Number of subjects: 0
Study 27620390 — intervention group
Group type: EXPERIMENTAL
Intervention: Achieved SBP of ≥150 mm Hg in patients aged ≥60 years
Number of subjects: 0
Study 27620390 — intervention group
Group type: EXPERIMENTAL
Intervention: Achieved SBP of 140 to 150 mm Hg in patients aged ≥60 years
Number of subjects: 0
Study 25496165 — intervention group
Group type: EXPERIMENTAL
Intervention: HLA-matched graft
Number of subjects: 654
Study 25496165 — intervention group
Group type: COMPARATOR
Intervention: Random graft
Number of subjects: 654
Study 22498739 — intervention group
Group type: EXPERIMENTAL
Intervention: IV zoledronic acid (ZOL)
Number of subjects: 1960
Study 22498739 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide, thalidomide, and dexamethasone (CTD)
Number of subjects: 1960
Study 22498739 — intervention group
Group type: COMPARATOR
Intervention: CTDa (attenuated oral CTD)
Number of subjects: 1960
Study 22498739 — intervention group
Group type: EXPERIMENTAL
Intervention: Thalidomide-containing regimens
Number of subjects: 1960
Study 22498739 — intervention group
Group type: EXPERIMENTAL
Intervention: ZOL
Number of subjects: 1960
Study 20420797 — intervention group
Group type: EXPERIMENTAL
Intervention: Chewed lanthanum
Number of subjects: 12
Study 20420797 — intervention group
Group type: EXPERIMENTAL
Intervention: Crushed lanthanum
Number of subjects: 12
Study 20420797 — intervention group
Group type: COMPARATOR
Intervention: Meal alone
Number of subjects: 12
Study 18539106 — intervention group
Group type: EXPERIMENTAL
Intervention: Denosumab every 3 months (Q3M; 6, 14, or 30 mg) or every 6 months (Q6M; 14, 60, 100, or 210 mg)
Number of subjects: 412
Study 18539106 — intervention group
Group type: EXPERIMENTAL
Intervention: Discontinuation of denosumab
Number of subjects: 412
Study 18539106 — intervention group
Group type: EXPERIMENTAL
Intervention: Retreatment with denosumab (60 mg Q6M)
Number of subjects: 412
Study 18539106 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 412
Study 18539106 — intervention group
Group type: EXPERIMENTAL
Intervention: Open-label oral alendronate weekly
Number of subjects: 412
Study 16182978 — intervention group
Group type: EXPERIMENTAL
Intervention: Specialized emergency nurses (SENs) applying Ottawa Ankle Rules (OAR)
Number of subjects: 106
Study 16182978 — intervention group
Group type: COMPARATOR
Intervention: House officers (HO) applying Ottawa Ankle Rules (OAR)
Number of subjects: 106
Study 16182978 — intervention group
Group type: EXPERIMENTAL
Intervention: Specialized emergency nurses (SENs) applying Ottawa Foot Rules (OFR)
Number of subjects: 106
Study 16182978 — intervention group
Group type: COMPARATOR
Intervention: House officers (HO) applying Ottawa Foot Rules (OFR)
Number of subjects: 106
Study 16182978 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall interobserver agreement for OAR
Number of subjects: 106
Study 16182978 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall interobserver agreement for OFR
Number of subjects: 106
Study 12867686 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketoprofen 2mg/kg
Number of subjects: 86
Study 12867686 — intervention group
Group type: COMPARATOR
Intervention: Pethidine 1mg/kg
Number of subjects: 86
Study 10557173 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-articular irrigation injection therapy
Number of subjects: 63
Study 10557173 — intervention group
Group type: COMPARATOR
Intervention: Intra-articular injection of steroid (Control)
Number of subjects: 63
Study 8687089 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefuroxime prophylaxis (3 g intravenous dose during induction of anaesthesia)
Number of subjects: 162
Study 8687089 — intervention group
Group type: COMPARATOR
Intervention: Control group (no cefuroxime prophylaxis)
Number of subjects: 162
Study 2104681 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholecystokinin-octapeptide (CCK-OP) 50 nanograms per kilogram intravenously over a ten minute period daily
Number of subjects: 15
Study 2104681 — intervention group
Group type: COMPARATOR
Intervention: Saline solution (placebo) intravenously
Number of subjects: 15
Study 2104681 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholecystokinin-octapeptide (CCK-OP)
Number of subjects: 15
Study 2104681 — intervention group
Group type: COMPARATOR
Intervention: Saline solution (placebo)
Number of subjects: 15
Study 318736 — intervention group
Group type: EXPERIMENTAL
Intervention: DES-exposed males
Number of subjects: 696
Study 318736 — intervention group
Group type: COMPARATOR
Intervention: Control males
Number of subjects: 696
Study 318736 — intervention group
Group type: EXPERIMENTAL
Intervention: DES-exposed females
Number of subjects: 696
Study 318736 — intervention group
Group type: COMPARATOR
Intervention: Control females
Number of subjects: 696
Study 31373036 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo drink (presumed energy drink information)
Number of subjects: 48
Study 31373036 — intervention group
Group type: COMPARATOR
Intervention: Standard water drink information
Number of subjects: 48
Study 29958619 — intervention group
Group type: EXPERIMENTAL
Intervention: Written discharge instructions in Spanish
Number of subjects: 20
Study 29958619 — intervention group
Group type: COMPARATOR
Intervention: Written discharge instructions in English
Number of subjects: 20
Study 29958619 — intervention group
Group type: EXPERIMENTAL
Intervention: Survey on patient satisfaction and preferences
Number of subjects: 20
Study 29958619 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient satisfaction
Number of subjects: 20
Study 27058204 — intervention group
Group type: EXPERIMENTAL
Intervention: Early rehabilitation and mobilization in addition to standard treatment
Number of subjects: 0
Study 27058204 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 0
Study 23241084 — intervention group
Group type: EXPERIMENTAL
Intervention: High cost sharing plans (95%)
Number of subjects: 2000
Study 23241084 — intervention group
Group type: COMPARATOR
Intervention: Low cost sharing plans (0, 25, 50%)
Number of subjects: 2000
Study 24094019 — intervention group
Group type: EXPERIMENTAL
Intervention: Elastic ligatures aged in the oral environment for 4 weeks
Number of subjects: 5
Study 24094019 — intervention group
Group type: COMPARATOR
Intervention: Control group of elastic ligatures not subjected to oral degradation
Number of subjects: 5
Study 20714187 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal bevacizumab 1.25 mg
Number of subjects: 18
Study 18450878 — intervention group
Group type: EXPERIMENTAL
Intervention: Observation therapy without prescription
Number of subjects: 232
Study 18450878 — intervention group
Group type: COMPARATOR
Intervention: Observation therapy with prescription
Number of subjects: 232
Study 16543909 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacist/physician collaboration
Number of subjects: 0
Study 16543909 — intervention group
Group type: EXPERIMENTAL
Intervention: JNC 7 measurement tool
Number of subjects: 0
Study 12694003 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical cleaning plus thermal disinfection at 90 degrees C
Number of subjects: 14
Study 12694003 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical cleaning plus thermal disinfection at 90 degrees C followed by steam sterilisation at 134 degrees C
Number of subjects: 14
Study 11574363 — intervention group
Group type: EXPERIMENTAL
Intervention: rapacuronium 1.2 mg/kg
Number of subjects: 80
Study 11574363 — intervention group
Group type: EXPERIMENTAL
Intervention: rapacuronium 1.0 mg/kg
Number of subjects: 80
Study 11574363 — intervention group
Group type: EXPERIMENTAL
Intervention: rocuronium 0.50 mg/kg
Number of subjects: 80
Study 11574363 — intervention group
Group type: COMPARATOR
Intervention: saline 0.05 mL/kg
Number of subjects: 80
Study 9763797 — intervention group
Group type: EXPERIMENTAL
Intervention: 50% of VO2max
Number of subjects: 30
Study 9763797 — intervention group
Group type: EXPERIMENTAL
Intervention: 60% of VO2max
Number of subjects: 30
Study 9763797 — intervention group
Group type: EXPERIMENTAL
Intervention: 70% of VO2max
Number of subjects: 30
Study 9763797 — intervention group
Group type: EXPERIMENTAL
Intervention: 80% of VO2max
Number of subjects: 30
Study 8298866 — intervention group
Group type: EXPERIMENTAL
Intervention: Tilted, optimized non-saturating excitation (TONE) customized RF pulses
Number of subjects: 10
Study 8298866 — intervention group
Group type: COMPARATOR
Intervention: FISP‐3D (Fast Imaging Steady Precession) pulse sequences without TONE
Number of subjects: 10
Study 3354808 — intervention group
Group type: EXPERIMENTAL
Intervention: bupivacaine 30 mg plus buprenorphine 0.03 mg (group B, n = 30)
Number of subjects: 90
Study 3354808 — intervention group
Group type: EXPERIMENTAL
Intervention: bupivacaine 30 mg plus buprenorphine 0.045 mg (group C, n = 30)
Number of subjects: 90
Study 3354808 — intervention group
Group type: COMPARATOR
Intervention: bupivacaine 30 mg (group A, n = 30)
Number of subjects: 90
Study 8445413 — intervention group
Group type: EXPERIMENTAL
Intervention: Active specific immunotherapy (ASI) with autologous tumor cell-BCG vaccine
Number of subjects: 80
Study 8445413 — intervention group
Group type: EXPERIMENTAL
Intervention: Active specific immunotherapy (ASI)
Number of subjects: 80
Study 8445413 — intervention group
Group type: COMPARATOR
Intervention: Resection alone
Number of subjects: 80
Study 354840 — intervention group
Group type: EXPERIMENTAL
Intervention: Benzopyranoperidine 2 mg
Number of subjects: 35
Study 354840 — intervention group
Group type: EXPERIMENTAL
Intervention: Benzopyranoperidine 4 mg
Number of subjects: 35
Study 354840 — intervention group
Group type: EXPERIMENTAL
Intervention: Codeine sulfate 60 mg
Number of subjects: 35
Study 354840 — intervention group
Group type: EXPERIMENTAL
Intervention: Codeine sulfate 120 mg
Number of subjects: 35
Study 354840 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study 31417244 — intervention group
Group type: EXPERIMENTAL
Intervention: Head lift exercise (HLE)
Number of subjects: 23
Study 31417244 — intervention group
Group type: COMPARATOR
Intervention: Neuromuscular electrical stimulation (NMES)
Number of subjects: 23
Study 27321436 — intervention group
Group type: EXPERIMENTAL
Intervention: Allergen exposure
Number of subjects: 0
Study 27321436 — intervention group
Group type: EXPERIMENTAL
Intervention: Diesel exhaust exposure
Number of subjects: 0
Study 27321436 — intervention group
Group type: EXPERIMENTAL
Intervention: Co-exposure to allergen and diesel exhaust
Number of subjects: 0
Study 27321436 — intervention group
Group type: EXPERIMENTAL
Intervention: Allergen followed by diesel exhaust exposure (4 weeks apart)
Number of subjects: 0
Study 27321436 — intervention group
Group type: EXPERIMENTAL
Intervention: Diesel exhaust followed by allergen exposure (4 weeks apart)
Number of subjects: 0
Study 27573034 — intervention group
Group type: EXPERIMENTAL
Intervention: CABG
Number of subjects: 1212
Study 27573034 — intervention group
Group type: COMPARATOR
Intervention: MED
Number of subjects: 1212
Study 24352875 — intervention group
Group type: EXPERIMENTAL
Intervention: CHELT (Cold air and High Energy Laser Therapy)
Number of subjects: 60
Study 24352875 — intervention group
Group type: COMPARATOR
Intervention: ESWT (Extracorporeal Shock Waves Therapy)
Number of subjects: 60
Study 22999730 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised exercise training (ET) at 60% of peak oxygen consumption, 2 times weekly for 10 years.
Number of subjects: 123
Study 22999730 — intervention group
Group type: COMPARATOR
Intervention: Non-trained group (NT) did not exercise formally.
Number of subjects: 123
Study 19443681 — intervention group
Group type: EXPERIMENTAL
Intervention: Etoricoxib 120 mg once daily with triphasic oral contraceptive (OC)
Number of subjects: 79
Study 19443681 — intervention group
Group type: EXPERIMENTAL
Intervention: Etoricoxib 60 mg once daily with triphasic oral contraceptive (OC)
Number of subjects: 79
Study 19443681 — intervention group
Group type: COMPARATOR
Intervention: Placebo with triphasic oral contraceptive (OC)
Number of subjects: 79
Study 19443681 — intervention group
Group type: EXPERIMENTAL
Intervention: Etoricoxib (both dosages) with triphasic oral contraceptive (OC)
Number of subjects: 79
Study 19443681 — intervention group
Group type: EXPERIMENTAL
Intervention: Etoricoxib and OC
Number of subjects: 79
Study 17302652 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive vision and eye examinations with subsequent treatment (new eyeglasses, referrals for occupational therapy, glaucoma management, cataract surgery)
Number of subjects: 616
Study 17302652 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 616
Study 17302652 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive vision and eye examinations with subsequent treatment
Number of subjects: 616
Study 15346658 — intervention group
Group type: COMPARATOR
Intervention: Transdermal 17beta‐estradiol 0.05 mg/day
Number of subjects: 140
Study 15346658 — intervention group
Group type: EXPERIMENTAL
Intervention: Tibolone 2.5 mg/day
Number of subjects: 140
Study 11996209 — intervention group
Group type: EXPERIMENTAL
Intervention: Formulation A (0.02 mg ethinylestradiol and 0.1 mg levonorgestrel)
Number of subjects: 67
Study 11996209 — intervention group
Group type: EXPERIMENTAL
Intervention: Formulation B (0.03 mg ethinylestradiol and 0.15 mg levonorgestrel)
Number of subjects: 67
Study 11996209 — intervention group
Group type: EXPERIMENTAL
Intervention: Formulation A
Number of subjects: 67
Study 11996209 — intervention group
Group type: EXPERIMENTAL
Intervention: Formulation B
Number of subjects: 67
Study 9822496 — intervention group
Group type: EXPERIMENTAL
Intervention: Prepidil with immediate oxytocin
Number of subjects: 150
Study 9822496 — intervention group
Group type: COMPARATOR
Intervention: Cervidil
Number of subjects: 150
Study 8004298 — intervention group
Group type: EXPERIMENTAL
Intervention: Eucapnic Voluntary Hyperventilation (EVH)
Number of subjects: 16
Study 8004298 — intervention group
Group type: COMPARATOR
Intervention: Eucapnic Voluntary Hyperventilation (EVH) after Methacholine Inhalation Challenge (MIC)
Number of subjects: 16
Study 8004298 — intervention group
Group type: EXPERIMENTAL
Intervention: Methacholine Inhalation Challenge (MIC)
Number of subjects: 16
Study 8004298 — intervention group
Group type: COMPARATOR
Intervention: Methacholine Inhalation Challenge (MIC) after Eucapnic Voluntary Hyperventilation (EVH)
Number of subjects: 16
Study 8004298 — intervention group
Group type: EXPERIMENTAL
Intervention: Subset of patients most sensitive to methacholine (PD20 < 0.1 breath unit) after Eucapnic Voluntary Hyperventilation (EVH)
Number of subjects: 16
Study 2529798 — intervention group
Group type: EXPERIMENTAL
Intervention: Loratadine 5 mg plus pseudoephedrine 120 mg twice a day
Number of subjects: 264
Study 2529798 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 264
Study 1096122 — intervention group
Group type: EXPERIMENTAL
Intervention: Clotrimazole cream
Number of subjects: 0
Study 1096122 — intervention group
Group type: COMPARATOR
Intervention: Tolnaftate cream
Number of subjects: 0
Study 1096122 — intervention group
Group type: COMPARATOR
Intervention: Nystatin cream
Number of subjects: 0
Study 31303397 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness Awareness Program (MAP)
Number of subjects: 55
Study 31303397 — intervention group
Group type: COMPARATOR
Intervention: Health Education Program (HEP)
Number of subjects: 55
Study 28677999 — intervention group
Group type: EXPERIMENTAL
Intervention: RT plus black mulberry molasses
Number of subjects: 80
Study 28677999 — intervention group
Group type: COMPARATOR
Intervention: RT
Number of subjects: 80
Study 24861717 — intervention group
Group type: COMPARATOR
Intervention: Human Patient Simulator (HAL)
Number of subjects: 80
Study 24861717 — intervention group
Group type: COMPARATOR
Intervention: Human Patient Simulator (SimMan)
Number of subjects: 80
Study 24861717 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients
Number of subjects: 80
Study 24861717 — intervention group
Group type: EXPERIMENTAL
Intervention: Endotracheal intubation
Number of subjects: 80
Study 23863328 — intervention group
Group type: EXPERIMENTAL
Intervention: Rabeprazole 0.5‐ or 1.0‐mg/kg granule formulation for 12 weeks (5 or 10 mg for low-weight cohort; 10 or 20 mg for high-weight cohort)
Number of subjects: 108
Study 23863328 — intervention group
Group type: EXPERIMENTAL
Intervention: Rabeprazole 0.5‐ or 1.0‐mg/kg granule formulation for 12 weeks
Number of subjects: 108
Study 21823172 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine long-acting injection (LAI) (150 mg/2 weeks, 405 mg/4 weeks, or 300 mg/2 weeks)
Number of subjects: 921
Study 21823172 — intervention group
Group type: COMPARATOR
Intervention: Oral olanzapine (10, 15, or 20 mg/day)
Number of subjects: 921
Study 21823172 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments (LAI and oral olanzapine)
Number of subjects: 921
Study 19635216 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg/kg ketamine infusion under general anesthesia and 0.1 mg/kg ketamine for 24 hours post-surgery
Number of subjects: 200
Study 19635216 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg/kg ketamine infusion under general anesthesia and 0.05 mg/kg ketamine for 24 hours post-surgery
Number of subjects: 200